RAPT Therapeutics, Inc. (RAPT) Research & Development (2020 - 2024)
RAPT Therapeutics' Research & Development history spans 5 years, with the latest figure at $46.5 million for Q4 2024.
- For Q4 2024, Research & Development rose 73.58% year-over-year to $46.5 million; the TTM value through Dec 2024 reached $107.2 million, up 6.15%, while the annual FY2024 figure was $107.2 million, 6.15% up from the prior year.
- Research & Development for Q4 2024 was $46.5 million at RAPT Therapeutics, up from $13.3 million in the prior quarter.
- Across five years, Research & Development topped out at $46.5 million in Q4 2024 and bottomed at $10.7 million in Q1 2020.
- The 5-year median for Research & Development is $16.2 million (2021), against an average of $18.9 million.
- The largest YoY upside for Research & Development was 73.58% in 2024 against a maximum downside of 50.63% in 2024.
- A 5-year view of Research & Development shows it stood at $10.9 million in 2020, then surged by 31.14% to $14.3 million in 2021, then surged by 36.05% to $19.5 million in 2022, then skyrocketed by 37.58% to $26.8 million in 2023, then skyrocketed by 73.58% to $46.5 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Research & Development are $46.5 million (Q4 2024), $13.3 million (Q3 2024), and $22.6 million (Q2 2024).